News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (343 of 400). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (16 of 400). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (41 of 400). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 297 of 400 items have one.
Clinical trial explores potential brain health benefits of dietary supplement
A dietary supplement called urolithin A increased blood flow to the brain during mental activity in middle-aged adults with obesity, according to a University of Oklahoma study published in JAMA Network Open. …
Read at Medical Xpress →Clinical trial tests AI-assisted medication device for older adults with memory loss
Marianne Blake has lived in the same home for nearly half a century. She plays bridge regularly, drives to her hair appointments and, at 88 years old, enjoys her independence.
Read at Medical Xpress →Pill form of semaglutide fails to slow Alzheimer's in large trial
A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.
Why it matters: A pill form of semaglutide failed to slow Alzheimer's disease progression in a large trial, Novo Nordisk announced on Nov. 24.
Read at Medical Xpress → Archived copy (6 Jan 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.